Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Bazinaprine

From Wikipedia, the free encyclopedia
Bazinaprine
Clinical data
ATC code
  • None
Identifiers
  • 3-{[2-(morpholin-4-yl)ethyl]amino}-6-phenylpyridazine-4-carbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H19N5O
Molar mass309.373 g·mol−1
3D model (JSmol)
  • N#Cc2cc(nnc2NCCN1CCOCC1)c3ccccc3
  • InChI=1S/C17H19N5O/c18-13-15-12-16(14-4-2-1-3-5-14)20-21-17(15)19-6-7-22-8-10-23-11-9-22/h1-5,12H,6-11H2,(H,19,21) checkY
  • Key:KRNDIPHOJLIHRI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro.[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.[2]

See also

[edit]

References

[edit]
  1. ^ Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K (April 1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44. doi:10.1111/j.1471-4159.1988.tb10584.x. PMID 3346672. S2CID 12521641.
  2. ^ Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K (January 1987). "SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition". The Journal of Pharmacology and Experimental Therapeutics. 240 (1): 251–8. PMID 3100771.